High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.
about
Cnidarians as a source of new marine bioactive compounds--an overview of the last decade and future steps for bioprospectingSmall-molecule inhibitors of myosin proteinsEnhanced fluorescence of proteins and label-free bioassays using aluminum nanostructuresApplication of parallel liquid chromatography/mass spectrometry for high throughput microsomal stability screening of compound libraries.Recent advances in pharmacokinetic extrapolation from preclinical data to humans.Cassette-accelerated rapid rat screen: a systematic procedure for the dosing and liquid chromatography/atmospheric pressure ionization tandem mass spectrometric analysis of new chemical entities as part of new drug discovery.Direct Mass Spectrometry Analysis of Untreated Samples of Ultralow Amounts Using Extraction Nano-Electrospray.PubChem3D: Biologically relevant 3-D similarityTOXICITY PROFILING OF ENGINEERED NANOMATERIALS VIA MULTIVARIATE DOSE-RESPONSE SURFACE MODELING.Optimization of metabolic stability as a goal of modern drug design.Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy.In vitro tests for predicting drug-drug interactions: the need for validated procedures.Cyto-genotoxicity Assessment of Potential Anti-tubercular Drug Candidate Molecule-trans-cyclohexane-1, 4-diamine Derivative-9u in Human Lung Epithelial Cells A549.Pharmacophore-based discovery of ligands for drug transporters.Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.Prediction of drug metabolism and interactions on the basis of in vitro investigations.NMR in pharmacokinetic and pharmacodynamic profiling.Impact of chrysosplenetin on the pharmacokinetics and anti-malarial efficacy of artemisinin against Plasmodium berghei as well as in vitro CYP450 enzymatic activities in rat liver microsomePharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents.Direct quantitative analysis of nicotine alkaloids from biofluid samples using paper spray mass spectrometry.Electrical cell-substrate impedance sensing as a non-invasive tool for cancer cell study.Current drug discovery strategies for treatment of hepatitis C virus infection.Recent advances in metabolite identification and quantitative bioanalysis by LC-Q-TOF MS.Methods for the quantitative evaluation and prediction of CYP enzyme induction using human in vitro systems.Advances in predicting CYP-mediated drug interactions in the drug discovery setting.Hepatic metabolism: a key component of herbal drugs research.Droplet-based microfluidics in drug discovery, transcriptomics and high-throughput molecular genetics.Micro-scaffold array chip for upgrading cell-based high-throughput drug testing to 3D using benchtop equipment.Design, synthesis, cytotoxic evaluation, and QSAR study of some 6H-indolo[2,3-b]quinoxaline derivatives.Cytochrome P450 structure-function: insights from molecular dynamics simulations.Molecular determinants of the interaction between Clostridium perfringens enterotoxin fragments and claudin-3.Protein targets of reactive electrophiles in human liver microsomes.A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.Rapid in vivo oral screening in rats: reliability, acceptance criteria, and filtering efficiency.Protective Effects of Vitamin C and NAC on the Toxicity of Rifampin on Hepg2 Cells.Ultra-performance hydrophilic interaction LC-MS/MS for the determination of metformin in mouse plasma.High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.A preliminary study on the feasibility of an automated blood-sampling system in conjunction with liquid chromatography/mass spectrometry.Characterization of human cytochrome P450 isoforms involved in the metabolism of 7-epi-paclitaxel.An Efficient and Rapid Method to Monitor the Oxidative Degradation of Protein Pharmaceuticals: Probing Tyrosine Oxidation with Fluorogenic Derivatization.
P2860
Q26859686-22DB9D17-7D02-4823-9585-9B05629B84E6Q27027635-ED11C18D-4EFA-404B-B402-7F19573BA90BQ28748295-BCF4E90E-BAF9-4355-80F1-B7D464D12A44Q31038437-504D9058-F0C1-407E-8FDE-285B07AC1AF7Q31049599-3FFD4946-A307-4760-B225-7D08E68EC9C5Q33422934-5BFE1B61-64F9-4FEE-870D-11C64D828439Q33460204-3C0ED916-B0F2-44B8-8BA8-01B8AC05BDCDQ33968874-B3D5F9BC-0A9A-4B58-B2A9-C79BA0239DE0Q34121124-E16E10E9-C868-4B11-92C9-6AC0F5FEFC14Q34386836-246444B6-340B-4C71-880E-0A8E37FE108DQ34975426-49015BBC-7255-4B31-A8CE-52B442A1F8E9Q35060620-86C3AA59-045E-4AD0-9D0C-79FCE6A88A93Q35153274-029EFBB4-C21A-452B-B6B8-C6BF09B9B21CQ35594214-ACAC3539-98CA-4AAA-A77F-F0CA16B4BFFCQ35863912-B147C79B-D0D0-4B17-B506-13C3FA8CA1AFQ36055562-86BB1342-3A11-4F22-B8C8-C2E2D1A9821DQ36211847-6511F980-79BF-42E2-B2DA-FF29E3CCEE41Q36246585-9D0B7FF2-5655-4EBB-BE03-0A3DA852B267Q37361955-215F7E98-489A-410C-BD17-02A5D96CA6D6Q37425440-9D51CD33-5CAB-4EF5-B20A-894D0A3AACE5Q37801844-725582AC-84DE-49F8-9DE4-86B44D8034D1Q37884087-5C8376CD-61E6-4B84-867E-86380DB74092Q38005438-072CD35D-CF65-4CD7-AC94-F1A2F0011306Q38028549-8F68C8FF-1379-481E-AB61-086D3B197E91Q38089823-14953E59-1C92-45C4-A42F-28AD80F6723DQ38258151-30757557-9736-4433-AB0C-C7C214019086Q38792900-CBE5CFFC-4004-4A82-8AD1-7C87C13EFD6FQ39052415-1F0EBD82-1DAA-4DBE-84DD-98980299C429Q39727104-EFD890C8-A365-4111-9581-AD75F00947B4Q39775781-7B6A3F0D-938F-45DF-930C-6E1D11E3BB20Q39853561-2DB9E1D6-C7C4-4AE9-8FE4-71E5DCFAA849Q40137121-6B0EB14D-4896-4ED2-900D-920451368012Q40376556-7395A81F-7ACF-4DC4-8A62-4DD530C2708FQ41960216-51E00F65-BF43-4F28-95DA-67AC78BA87B9Q42781717-5721817B-4275-42B3-BC85-24E57BD84370Q42807323-F06D98F9-B90D-43F6-9FB6-EDD19702DB24Q43602056-52CCC9A2-545E-4654-AB6F-5C91B0AE528AQ43736659-80F48F07-06D9-4C74-B2C5-CE5FB3A471BFQ46059077-CFDE1E51-BB06-4FBC-9F9C-5808CDBFFB2EQ46149367-AD9948B2-D303-4EA6-95F1-6C5F5BABA159
P2860
High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
High-throughput screening in d ...... tic support of drug discovery.
@ast
High-throughput screening in d ...... tic support of drug discovery.
@en
type
label
High-throughput screening in d ...... tic support of drug discovery.
@ast
High-throughput screening in d ...... tic support of drug discovery.
@en
prefLabel
High-throughput screening in d ...... tic support of drug discovery.
@ast
High-throughput screening in d ...... tic support of drug discovery.
@en
P1476
High-throughput screening in d ...... tic support of drug discovery.
@en
P2093
P304
P356
10.1146/ANNUREV.PHARMTOX.40.1.133
P577
2000-01-01T00:00:00Z